Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Shweta Supriya Pradhan"'
Autor:
Elisha Paikray, Manoranjan Pattnaik, Vedvyas Mishra, Parida Ansuman Abhisek, Shweta Supriya Pradhan, Anima Rout
Publikováno v:
Journal of Family Medicine and Primary Care, Vol 13, Iss 10, Pp 4684-4692 (2024)
Background The foremost concern and challenge in managing drug-resistant tuberculosis is ensuring a high health-related quality of life (HRQoL). The effectiveness of pre-extensively drug-resistant (Pre-XDR) tuberculosis management hinges on patients
Externí odkaz:
https://doaj.org/article/402f329d459f450f82691f61abe41ce8
Publikováno v:
Journal of Clinical and Diagnostic Research, Vol 14, Iss 12, Pp FC16-FC32 (2020)
Introduction: It is a crucial time for the medical community to cope up with novel Coronavirus Disease 2019 (COVID-19). The empirical evidence for the effectiveness of Hydroxychloroquine (HCQ) in COVID-19 is currently very limited. So in this cont
Externí odkaz:
https://doaj.org/article/6b65ec37861540a49215d9cf48b62fc4
Publikováno v:
International Journal of Medical Engineering and Informatics. 13:1
This was a prospective, observational study conducted to assess prevalence of different spectrum of DDIs in MR/XDR TB patients by analyzing 42 prescriptions. DDIs were analysed by softwares like Lexicomp, Micromedex, and Drugs.com, Medscape.com. Only
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7a0e5f7c2bd3c44960fb12f4e498a693
https://doi.org/10.1504/ijmei.2021.10023396
https://doi.org/10.1504/ijmei.2021.10023396
Publikováno v:
International Journal of Medical Engineering and Informatics. 12:260
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b1e030b5f93009065f96f9cac6676402
https://doi.org/10.1504/ijmei.2020.107092
https://doi.org/10.1504/ijmei.2020.107092
Autor:
Sidharth Srabana Routray, P. Ansuman Abhisek, Lalit Mohan Sika, Rajendra Panda, Srikanta Mohanty, Shweta Supriya Pradhan
Publikováno v:
International Journal of Basic & Clinical Pharmacology. 8:1951
Background: Antimicrobial agents (AMAs) are the most frequently used drugs in the intensive care units (ICU) and regular auditing can prevent the development of resistance to AMAs, reduce the cost and incidence of adverse drug reactions. The present
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::01e8bf8517e9f884b287a934ccda8f01
https://doi.org/10.18203/2319-2003.ijbcp20193672
https://doi.org/10.18203/2319-2003.ijbcp20193672